Abstract 2533
Background
ICIs are pivotal therapies in the treatment of pts with R/M HNSCC. The dismal OS of some pts underscores the need to detect pre-treatment prognostic scores.
Methods
Pts with R/M HNSCC receiving pembrolizumab (P) or nivolumab (N) were included in this retrospective analysis. We analyzed the impact of the following pre-treatment variables for OS using a Cox proportional hazards regression model: drug type, age, sex, tumor site, line of therapy, p-16, albumin (alb), hemoglobin (Hb), lactic dehydrogenase (LDH), lymphocyte count (LC), platelets (PLT), and neutrophil counts (NC).
Results
66 pts (55%) treated with N and 55 (45%) with P were included. Characteristics: Sex: Male 100 pts (83%), female 21 pts (17%); Mean Age: 62 (SD 11); Performance Status 0-1: 63 pts (52%), 2-3: 58 pts (48%); Line of therapy, 1: 43 pts (36%), 2: 58 pts (48%), 3-4: 20 pts (16%); P-16: positive 44 pts (36%), negative 77 pts (64%); Tumor site: oropharynx 54 pts (45%), oral cavity 23 pts (19%), larynx 16 pts (13%), other 28 pts (23%); Response: complete 11 pts (9%), partial 3 pts (2%), stable disease 47 pts (39%); and disease progression: 60 pts (50%). The OS at 1 and 2 years were 52% (95% confidence interval (CI), 43%-62%) and 27% (CI 17%-42%), respectively. Age, sex, PLT, NC, LC, p-16, alb, Hb, and LDH were included in the multivariable Cox model. Adjusted hazard ratio estimates are: P-16: 0.53 (CI 0.3-0.95, P = 0.03); LC: 0.67 (CI 0.46-0.97, P = 0.03); NC: 1.25 (CI 1.01-1.56, P = 0.04); LDH: 1.67 (CI 1.01-2.78, P = 0.04); Hb: 1.69 (CI 1.00-2.87, P = 0.05); alb: 1.69 (CI 0.94-3.02, P = 0.08); PLT: 1.06 (CI 0.82, 1.37, P = 0.7); Age: 1.02 (CI 0.78-1.34, P = 0.9); and Sex: 0.98 (CI 0.5-1.91, P = 0.9). This model was used to create a nomogram based prognostic score for 1 and 2 year OS probability and median OS time. Internal model validation using bootstrapped based bias corrected estimates showed Nagelkerke’s R2 = 0.18, calibration slope of 0.67, and C-index of 0.7.
Conclusions
Pre-treatment LC, NC as well as LDH, Hb, alb, and p-16 had the largest impact on OS based on a prognostic nomogram. The nomogram may help treatment decisions regarding ICI use in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3073 - 1 patient 3 different advance Ca nurse’s roles: symptom management&continuum care through a joint approach in a clinical case
Presenter: Catarina Almeida
Session: Poster Display session 3
Resources:
Abstract
4527 - Identification of malnutrition risk factors in patients with cancer in the first nursing visit
Presenter: Amaia Valverde
Session: Poster Display session 3
Resources:
Abstract
2904 - Engaging Cancer Survivors, Healthcare Providers and Advocates in The Development of a Colorectal Cancer Survivorship Information Resource: A Participatory Action Research Study
Presenter: Amanda Drury
Session: Poster Display session 3
Resources:
Abstract
3435 - Medical nurses’ experiences of the care-needs of adult patients with a primary brain tumour
Presenter: Jamila Mohammed
Session: Poster Display session 3
Resources:
Abstract
857 - Feasibility and acceptability of a mHealth intervention to increase colonoscopy uptake among Chinese first-degree relatives: a pilot cluster randomized controlled trial
Presenter: Yang Bai
Session: Poster Display session 3
Resources:
Abstract
1087 - Cancer patient participation and compliance in microbiome sample collection: an oncology research nurse’s experience
Presenter: Julie Malo
Session: Poster Display session 3
Resources:
Abstract
2783 - Implementing Digital Individual Care plans for Patients with Head and Neck cancer- Challenges and opportunities
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract
1152 - The Effect of the Short-term and Long-term Compassion Fatigue Resiliency Program on the Quality of Life, Perceived Stress and Psychological Resilience of Oncology-Hematology Nurses
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
1172 - Competing risk analyses of overall survival and cancer-specific survival in patients with orbital rhabdomyosarcoma after surgery: a large cohort study
Presenter: Yu Zhang
Session: Poster Display session 3
Resources:
Abstract
5949 - Communication of genetic information to family members in hereditary cancers and healthcare providers’ role
Presenter: Carla Pedrazzani
Session: Poster Display session 3
Resources:
Abstract